• Hims & Hers entered an agreement with Eli Lilly to expand access to FDA-approved obesity medicines Zepbound and Foundayo through its platform.
• Eligible patients prescribed treatment can receive home delivery without leaving the platform, at the same self-pay prices available to other patients.
• Monthly self-pay pricing starts at $149 for Foundayo and $299 for Zepbound.
• The platform committed not to offer compounded copies of Lilly’s GLP-1 medicines, while both companies pledged to protect independent prescribing decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611060647BIZWIRE_USPR_____20261106_BW567564) on November 06, 2026, and is solely responsible for the information contained therein.